For High-Definition, Click
Several new therapies have recently become available or are under exploration for the treatment of patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL). In 2012 the FDA granted accelerated approval for vincristine sulfate liposome injection (Marqibo) for the treatment of adult patients with Ph-negative ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
In addition to this therapy, the many T cells therapies coming down the line are extremely exciting, panelists believe. Moreover, the cytokine release syndrome of the CAR therapies or the infusion-related status epilepticus of blinatumomab appear manageable, even outside of academic settings. Additionally, the technology utilized to measure response has increased greatly with the introduction of minimal residual disease tests.